The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer

C. Aristei; O. Kaidar-Person; L. Boersma; M. C. Leonardi; B. Offersen; P. Franco; M. Arenas; C. Bourgier; R. Pfeffer; V. Kouloulias; Y. Bölükbaşı; I. Meattini; C. Coles; A. Montero Luis; V. Masiello; I. Palumbo; A. G. Morganti; E. Perrucci; V. Tombolini; M. Krengli; F. Marazzi; L. Trigo; S. Borghesi; A. Ciabattoni; I. Ratoša; V. Valentini; P. Poortmans

doi:10.1016/j.critrevonc.2023.104035

The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer

C. Aristei, O. Kaidar-Person, L. Boersma, M. C. Leonardi, B. Offersen, P. Franco, M. Arenas, C. Bourgier, R. Pfeffer, V. Kouloulias, Y. Bölükbaşı, I. Meattini, C. Coles, A. Montero Luis, V. Masiello, I. Palumbo, A. G. Morganti, E. Perrucci, V. Tombolini, M. KrengliF. Marazzi, L. Trigo, S. Borghesi, A. Ciabattoni, I. Ratoša, V. Valentini, P. Poortmans

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo di review › peer review

Abstract

The present white paper, referring to the 4th Assisi Think Tank Meeting on breast cancer, reviews state-of-the-art data, on-going studies and research proposals. <70% agreement in an online questionnaire identified the following clinical challenges: 1: Nodal RT in patients who have a) 1–2 positive sentinel nodes without ALND (axillary lymph node dissection); b) cN1 disease transformed into ypN0 by primary systemic therapy and c) 1–3 positive nodes after mastectomy and ALND. 2. The optimal combination of RT and immunotherapy (IT), patient selection, IT-RT timing, and RT optimal dose, fractionation and target volume. Most experts agreed that RT- IT combination does not enhance toxicity. 3: Re-irradiation for local relapse converged on the use of partial breast irradiation after second breast conserving surgery. Hyperthermia aroused support but is not widely available. Further studies are required to finetune best practice, especially given the increasing use of re-irradiation.

Lingua originale	Inglese
Numero di articolo	104035
Rivista	Critical Reviews in Oncology/Hematology
Volume	187
DOI	https://doi.org/10.1016/j.critrevonc.2023.104035
Stato di pubblicazione	Pubblicato - lug 2023

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/j.critrevonc.2023.104035

Altri file e collegamenti

Link to publication in Scopus

Cita questo

Aristei, C., Kaidar-Person, O., Boersma, L., Leonardi, M. C., Offersen, B., Franco, P., Arenas, M., Bourgier, C., Pfeffer, R., Kouloulias, V., Bölükbaşı, Y., Meattini, I., Coles, C., Luis, A. M., Masiello, V., Palumbo, I., Morganti, A. G., Perrucci, E., Tombolini, V., ... Poortmans, P. (2023). The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer. Critical Reviews in Oncology/Hematology, 187, Articolo 104035. https://doi.org/10.1016/j.critrevonc.2023.104035

@article{e4e0e518725a487dad7195ad43f95fd0,

title = "The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer",

abstract = "The present white paper, referring to the 4th Assisi Think Tank Meeting on breast cancer, reviews state-of-the-art data, on-going studies and research proposals. <70\% agreement in an online questionnaire identified the following clinical challenges: 1: Nodal RT in patients who have a) 1–2 positive sentinel nodes without ALND (axillary lymph node dissection); b) cN1 disease transformed into ypN0 by primary systemic therapy and c) 1–3 positive nodes after mastectomy and ALND. 2. The optimal combination of RT and immunotherapy (IT), patient selection, IT-RT timing, and RT optimal dose, fractionation and target volume. Most experts agreed that RT- IT combination does not enhance toxicity. 3: Re-irradiation for local relapse converged on the use of partial breast irradiation after second breast conserving surgery. Hyperthermia aroused support but is not widely available. Further studies are required to finetune best practice, especially given the increasing use of re-irradiation.",

keywords = "Breast cancer, Combined modality treatment, Immunotherapy, Radiation therapy, Re-irradiation in relapsed patients",

author = "C. Aristei and O. Kaidar-Person and L. Boersma and Leonardi, \{M. C.\} and B. Offersen and P. Franco and M. Arenas and C. Bourgier and R. Pfeffer and V. Kouloulias and Y. B{\"o}l{\"u}kba{\c s}ı and I. Meattini and C. Coles and Luis, \{A. Montero\} and V. Masiello and I. Palumbo and Morganti, \{A. G.\} and E. Perrucci and V. Tombolini and M. Krengli and F. Marazzi and L. Trigo and S. Borghesi and A. Ciabattoni and I. Rato{\v s}a and V. Valentini and P. Poortmans",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = jul,

doi = "10.1016/j.critrevonc.2023.104035",

language = "English",

volume = "187",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

}

Aristei, C, Kaidar-Person, O, Boersma, L, Leonardi, MC, Offersen, B, Franco, P, Arenas, M, Bourgier, C, Pfeffer, R, Kouloulias, V, Bölükbaşı, Y, Meattini, I, Coles, C, Luis, AM, Masiello, V, Palumbo, I, Morganti, AG, Perrucci, E, Tombolini, V, Krengli, M, Marazzi, F, Trigo, L, Borghesi, S, Ciabattoni, A, Ratoša, I, Valentini, V & Poortmans, P 2023, 'The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer', Critical Reviews in Oncology/Hematology, vol. 187, 104035. https://doi.org/10.1016/j.critrevonc.2023.104035

TY - JOUR

T1 - The 2022 Assisi Think Tank Meeting

T2 - White paper on optimising radiation therapy for breast cancer

AU - Aristei, C.

AU - Kaidar-Person, O.

AU - Boersma, L.

AU - Leonardi, M. C.

AU - Offersen, B.

AU - Franco, P.

AU - Arenas, M.

AU - Bourgier, C.

AU - Pfeffer, R.

AU - Kouloulias, V.

AU - Bölükbaşı, Y.

AU - Meattini, I.

AU - Coles, C.

AU - Luis, A. Montero

AU - Masiello, V.

AU - Palumbo, I.

AU - Morganti, A. G.

AU - Perrucci, E.

AU - Tombolini, V.

AU - Krengli, M.

AU - Marazzi, F.

AU - Trigo, L.

AU - Borghesi, S.

AU - Ciabattoni, A.

AU - Ratoša, I.

AU - Valentini, V.

AU - Poortmans, P.

PY - 2023/7

Y1 - 2023/7

N2 - The present white paper, referring to the 4th Assisi Think Tank Meeting on breast cancer, reviews state-of-the-art data, on-going studies and research proposals. <70% agreement in an online questionnaire identified the following clinical challenges: 1: Nodal RT in patients who have a) 1–2 positive sentinel nodes without ALND (axillary lymph node dissection); b) cN1 disease transformed into ypN0 by primary systemic therapy and c) 1–3 positive nodes after mastectomy and ALND. 2. The optimal combination of RT and immunotherapy (IT), patient selection, IT-RT timing, and RT optimal dose, fractionation and target volume. Most experts agreed that RT- IT combination does not enhance toxicity. 3: Re-irradiation for local relapse converged on the use of partial breast irradiation after second breast conserving surgery. Hyperthermia aroused support but is not widely available. Further studies are required to finetune best practice, especially given the increasing use of re-irradiation.

AB - The present white paper, referring to the 4th Assisi Think Tank Meeting on breast cancer, reviews state-of-the-art data, on-going studies and research proposals. <70% agreement in an online questionnaire identified the following clinical challenges: 1: Nodal RT in patients who have a) 1–2 positive sentinel nodes without ALND (axillary lymph node dissection); b) cN1 disease transformed into ypN0 by primary systemic therapy and c) 1–3 positive nodes after mastectomy and ALND. 2. The optimal combination of RT and immunotherapy (IT), patient selection, IT-RT timing, and RT optimal dose, fractionation and target volume. Most experts agreed that RT- IT combination does not enhance toxicity. 3: Re-irradiation for local relapse converged on the use of partial breast irradiation after second breast conserving surgery. Hyperthermia aroused support but is not widely available. Further studies are required to finetune best practice, especially given the increasing use of re-irradiation.

KW - Breast cancer

KW - Combined modality treatment

KW - Immunotherapy

KW - Radiation therapy

KW - Re-irradiation in relapsed patients

UR - https://www.scopus.com/pages/publications/85160571618

U2 - 10.1016/j.critrevonc.2023.104035

DO - 10.1016/j.critrevonc.2023.104035

M3 - Review article

SN - 1040-8428

VL - 187

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

M1 - 104035

ER -

The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo